Sepsis: Something old, something new, and a systems view

Journal of Critical Care

Volumn 27, Issue 3, 2012, Pages 314.e1-314.e11

  Namas, Rami ^a   Zamora, Ruben ^a   Namas, Rajaie ^a   An, Gary ^b,j   Doyle, John ^c   Dick, Thomas E ^d   Jacono, Frank J ^d,e   Androulakis, Ioannis P ^f   Nieman, Gary F ^g   Chang, Steve ^h   Billiar, Timothy R ^a   Kellum, John A ⁱ   Angus, Derek C ⁱ   Vodovotz, Yoram ^a,j  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^f The State University of New Jersey   (United States)

^g State University of New York Upstate Medical University: College of Medicine   (United States)

^h IMMUNETRICS INC   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

Inflammatory response; Mathematical model; Physiologic variability; Sepsis

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CELL PROTEIN; CYTOKINE RECEPTOR ANTAGONIST; DAMAGE ASSOCIATED MOLECULAR PATTERN MOLECULE; EARLY GROWTH RESPONSE FACTOR 1; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN MOLECULE; PATTERN RECOGNITION RECEPTOR; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; STAT1 PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AIR CONDITIONING; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING; BREATHING PATTERN; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; HEART RATE VARIABILITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MATHEMATICAL MODEL; MOLECULAR PATHOLOGY; PATHOGENESIS; SEPSIS; SIGNAL TRANSDUCTION; SIMULATION;

EID: 84861199459     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2011.05.025     Document Type: Article

References (158)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
2. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
3. Vincent J.L., Sakr Y., Sprung C.L., et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
4. Heron M., Hoyert D.L., Murphy S.L., et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009, 57:1-134.
5. Weycker D., Akhras K.S., Edelsberg J., et al. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med 2003, 31:2316-2323.
6. Wheeler A.P., Bernard G.R. Treating patients with severe sepsis. N Engl J Med 1999, 340:207-214.
7. Angus D.C., Wax R.S. Epidemiology of sepsis: an update. Crit Care Med 2001, 29:S109-S116.
8. Sands K.E., Bates D.W., Lanken P.N., et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997, 278:234-240.
9. Hoyert D.L., Arias E., Smith B.L., et al. Deaths: final data for 1999. Natl Vital Stat Rep 2001, 49:1-113.
10. Increase in National Hospital Discharge Survey rates for septicemia-United States, 1979-1987. MMWR Morb Mortal Wkly Rep 1990, 39:31-34.
11. Heyland D.K., Hopman W., Coo H., et al. Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000, 28:3599-3605.
12. Perl T.M., Dvorak L., Hwang T., et al. Long-term survival and function after suspected gram-negative sepsis. JAMA 1995, 274:338-345.
13. Protti A., Singer M. Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure. Crit Care 2006, 10:228.
14. Balestra G.M., Legrand M., Ince C. Microcirculation and mitochondria in sepsis: getting out of breath. Curr Opin Anaesthesiol 2009, 22:184-190.
15. Aird W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101:3765-3777.
16. Ait-Oufella H., Maury E., Lehoux S., et al. The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Med 2010, 36:1286-1298.
17. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787.
18. Levi M., van der Poll T. Inflammation and coagulation. Crit Care Med 2010, 38:S26-S34.
19. Geroulanos S., Douka E.T. Historical perspective of the word "sepsis". Intensive Care Med 2006, 32:2077.
20. Ewald P.W. Evolution of virulence. Infect Dis Clin North Am 2004, 18:1-15.
21. Vincent J.L. Clinical sepsis and septic shock-definition, diagnosis and management principles. Langenbecks Arch Surg 2008, 393:817-824.
22. Schottmueller H. Wesen und Behandlung der Sepsis. Inn Med 2009, 31:257-280.
23. An G. Agent-based computer simulation and sirs: building a bridge between basic science and clinical trials. Shock 2001, 16:266-273.
24. Buchman T.G., Cobb J.P., Lapedes A.S., et al. Complex systems analysis: a tool for shock research. Shock 2001, 16:248-251.
25. Kitano H. Systems biology: a brief overview. Science 2002, 295:1662-1664.
26. Neugebauer E.A., Willy C., Sauerland S. Complexity and non-linearity in shock research: reductionism or synthesis?. Shock 2001, 16:252-258.
27. Tjardes T., Neugebauer E. Sepsis research in the next millennium: concentrate on the software rather than the hardware. Shock 2002, 17:1-8.
28. Vodovotz Y., Clermont G., Chow C., et al. Mathematical models of the acute inflammatory response. Curr Opin Crit Care 2004, 10:383-390.
29. Vodovotz Y., Csete M., Bartels J., et al. Translational systems biology of inflammation. PLoS Comput Biol 2008, 4:e1000014.
30. Cohen M.J., Grossman A.D., Morabito D., et al. Identification of complex metabolic states in critically injured patients using bioinformatic cluster analysis. Crit Care 2010, 14:R10.
31. An G. In-silico experiments of existing and hypothetical cytokine-directed clinical trials using agent based modeling. Crit Care Med 2004, 32:2050-2060.
32. Strieter R.M., Lynch J.P., Basha M.A., et al. Host responses in mediating sepsis and adult respiratory distress syndrome. Semin Respir Infect 1990, 5:233-247.
33. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
34. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256.
35. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
36. Chung T.P., Laramie J.M., Province M., et al. Functional genomics of critical illness and injury. Crit Care Med 2002, 30:S51-S57.
37. Cobb J.P., O'Keefe G.E. Injury research in the genomic era. Lancet 2004, 363:2076-2083.
38. Godin P.J., Buchman T.G. Uncoupling of biological oscillators: a complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 1996, 24:1107-1116.
39. Buchman T.G. Nonlinear dynamics, complex systems, and the pathobiology of critical illness. Curr Opin Crit Care 2004, 10:378-382.
40. Seely A.J., Macklem P.T. Complex systems and the technology of variability analysis. Crit Care 2004, 8:R367-R384.
41. Vodovotz Y., Csete M., Bartels J., et al. Translational systems biology of inflammation. PLoS Comput Biol 2008, 4:1-6.
42. Vodovotz Y., Constantine G., Rubin J., et al. Mechanistic simulations of inflammation: current state and future prospects. Math Biosci 2009, 217:1-10.
43. Ventetuolo C.E., Levy M.M. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008, 29:591-603. vii.
44. Claus R.A., Otto G.P., Deigner H.P., et al. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. Curr Mol Med 2010, 10:227-235.
45. Bone R.C., Grodzin C.J., Balk R.A. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997, 112:235-243.
46. Vincent J.L., Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med 2006, 173:256-263.
47. Cinel I., Opal S.M. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009, 37:291-304.
48. Vodovotz Y., Chow C.C., Bartels J., et al. In silico models of acute inflammation in animals. Shock 2006, 26:235-244.
49. Mi Q., Li N.Y.K., Ziraldo C., et al. Translational systems biology of inflammation: potential applications to personalized medicine. Personalized Med 2010, 7:549-559.
50. Namas R., Ghuma A., Torres A., et al. An adequately robust early TNF-a response is a hallmark of survival following trauma/hemorrhage. PLoS ONE 2009, 4:e8406.
51. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
52. Fink M.P., Delude R.L. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin 2005, 21:177-196.
53. Marshall J.C. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001, 29:S99-106.
54. Jarrar D., Chaudry I.H., Wang P. Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches (review). Int J Mol Med 1999, 4:575-583.
55. Crouser E., Exline M., Knoell D., et al. Sepsis: links between pathogen sensing and organ damage. Curr Pharm Des 2008, 14:1840-1852.
56. Creagh E.M., O'Neill L.A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006, 27:352-357.
57. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
58. Granucci F., Foti M., Ricciardi-Castagnoli P. Dendritic cell biology. Adv Immunol 2005, 88:193-233.
59. Nduka O.O., Parrillo J.E. The pathophysiology of septic shock. Crit Care Clin 2009, 25:677-702. vii.
60. Cinel I., Dellinger R.P. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007, 20:345-352.
61. Opitz B., Eitel J., Meixenberger K., et al. Role of Toll-like receptors, NOD-like receptors and RIG-I-like receptors in endothelial cells and systemic infections. Thromb Haemost 2009, 102:1103-1109.
62. Arcaroli J., Fessler M.B., Abraham E. Genetic polymorphisms and sepsis. Shock 2005, 24:300-312.
63. Gibot S., Cariou A., Drouet L., et al. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002, 30:969-973.
64. Paterson H.M., Murphy T.J., Purcell E.J., et al. Injury primes the innate immune system for enhanced Toll-like receptor reactivity. J Immunol 2003, 171:1473-1483.
65. Vogel S.N., Awomoyi A.A., Rallabhandi P., et al. Mutations in TLR4 signaling that lead to increased susceptibility to infection in humans: an overview. J Endotoxin Res 2005, 11:333-339.
66. Pritts T., Hungness E., Wang Q., et al. Mucosal and enterocyte IL-6 production during sepsis and endotoxemia-role of transcription factors and regulation by the stress response. Am J Surg 2002, 183:372-383.
67. van der Poll T., van Deventer S.J. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999, 13:413-426. ix.
68. Adrie C., Pinsky M.R. The inflammatory balance in human sepsis. Intensive Care Med 2000, 26:364-375.
69. Maier R.V. Pathogenesis of multiple organ dysfunction syndrome-endotoxin, inflammatory cells, and their mediators: cytokines and reactive oxygen species. Surg Infect(Larchmt) 2000, 1:197-205.
70. Ulloa L., Tracey K.J. The "cytokine profile": a code for sepsis. Trends Mol Med 2005, 11:56-63.
71. Jawa R.S., Kulaylat M.N., Baumann H., et al. What is new in cytokine research related to trauma/critical care. J Intensive Care Med 2006, 21:63-85.
72. Pinsky M.R. Sepsis and multiple organ failure. Contrib Nephrol 2007, 156:47-63.
73. Cai B., Deitch E.A., Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm 2010, 2010:642462.
74. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635.
75. Hoffmann A., Levchenko A., Scott M.L., et al. The IkB-NFkB signaling module: temporal control and selective gene activation. Science 2002, 298:1241-1245.
76. Kellum J.A., Kong L., Fink M.P., et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007, 167:1655-1663.
77. Goldie A.S., Fearon K.C., Ross J.A., et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995, 274:172-177.
78. van der Poll T., de Waal M.R., Coyle S.M., et al. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997, 175:118-122.
79. Abraham E., Anzueto A., Gutierrez G., et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998, 351:929-933.
80. Reinhart K., Menges T., Gardlund B., et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES Study. Crit Care Med 2001, 29:765-769.
81. Pinsky M.R. Dysregulation of the immune response in severe sepsis. Am J Med Sci 2004, 328:220-229.
82. van der Poll T., Opal S.M. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008, 8:32-43.
83. dib-Conquy M., Cavaillon J.M. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007, 581:3723-3733.
84. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
85. Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573.
86. Angus D.C., Yang L., Kong L., et al. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 2007, 35:1061-1067.
87. Yang H., Ochani M., Li J., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004, 101:296-301.
88. Skoberne M., Beignon A.S., Bhardwaj N. Danger signals: a time and space continuum. Trends Mol Med 2004, 10:251-257.
89. Zhang Q., Raoof M., Chen Y., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.
90. Leon C.G., Tory R., Jia J., et al. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. PharmRes 2008, 25:1751-1761.
91. Hennessy E.J., Parker A.E., O'Neill L.A. Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov 2010, 9:293-307.
92. Wittebole X., Castanares-Zapatero D., Laterre P.F. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm 2010, 2010:568396.
93. Klune J.R., Dhupar R., Cardinal J., et al. HMGB1: endogenous danger signaling. Mol Med 2008, 14:476-484.
94. Wang H., Ward M.F., Sama A.E. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009, 32:348-357.
95. Yang H., Tracey K.J. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010, 1799:149-156.
96. Adams J.L., Badger A.M., Kumar S., et al. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog Med Chem 2001, 38:1-60.
97. Calzado M.A., Bacher S., Schmitz M.L. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 2007, 14:367-376.
98. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol 2008, 75:1567-1579.
99. Namas R., Ghuma A., Hermus L., et al. The acute inflammatory response in trauma/hemorrhage and traumatic brain injury: current state and emerging prospects. Libyan J Med 2009, 4:136-148.
100. Vodovotz Y., An G. Systems biology and inflammation. Systems Biology in Drug Discovery and Development: Methods and Protocols 2009, 181-201. Springer Science & Business Media, Totowa (NJ). Q. Yan (Ed.).
101. Vodovotz Y., Constantine G., Faeder J., et al. Translational systems approaches to the biology of inflammation and healing. Immunopharmacol Immunotoxicol 2010, 32:181-195.
102. Annane D., Trabold F., Sharshar T., et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med 1999, 160:458-465.
103. Korach M., Sharshar T., Jarrin I., et al. Cardiac variability in critically ill adults: influence of sepsis. Crit Care Med 2001, 29:1380-1385.
104. Piepoli M., Garrard C.S., Kontoyannis D.A., et al. Autonomic control of the heart and peripheral vessels in human septic shock. Intensive Care Med 1995, 21:112-119.
105. Fairchild K.D., Saucerman J.J., Raynor L.L., et al. Endotoxin depresses heart rate variability in mice: cytokine and steroid effects. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1019-R1027.
106. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996, 17:354-381.
107. Kleiger R.E., Stein P.K., Bigger J.T. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005, 10:88-101.
108. Pomeranz B., Macaulay R.J., Caudill M.A., et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985, 248:H151-H153.
109. Godin P.J., Fleisher L.A., Eidsath A., et al. Experimental human endotoxemia increases cardiac regularity: results from a prospective, randomized, crossover trial. Crit Care Med 1996, 24:1117-1124.
110. Barnaby D., Ferrick K., Kaplan D.T., et al. Heart rate variability in emergency department patients with sepsis. Acad Emerg Med 2002, 9:661-670.
111. Chen W.L., Kuo C.D. Characteristics of heart rate variability can predict impending septic shock in emergency department patients with sepsis. Acad Emerg Med 2007, 14:392-397.
112. Pontet J., Contreras P., Curbelo A., et al. Heart rate variability as early marker of multiple organ dysfunction syndrome in septic patients. J Crit Care 2003, 18:156-163.
113. Ahmad S., Ramsay T., Huebsch L., et al. Continuous multi-parameter heart rate variability analysis heralds onset of sepsis in adults. PLoS ONE 2009, 4:e6642.
114. Magder S. Bench-to-bedside review: ventilatory abnormalities in sepsis. Crit Care 2009, 13:202.
115. Preas H.L., Jubran A., Vandivier R.W., et al. Effect of endotoxin on ventilation and breath variability: role of cyclooxygenase pathway. Am J Respir Crit Care Med 2001, 164:620-626.
116. Cancio L.C., Batchinsky A.I., Salinas J., et al. Heart-rate complexity for prediction of prehospital lifesaving interventions in trauma patients. J Trauma 2008, 65:813-819.
117. Bone R.C. Why sepsis trials fail. JAMA 1996, 276:565-566.
118. Seely A.J., Christou N.V. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med 2000, 28:2193-2200.
119. Vodovotz Y. Deciphering the complexity of acute inflammation using mathematical models. Immunol Res 2006, 36:237-245.
120. Marshall J.C. Through a glass darkly: the brave new world of in silico modeling. Crit Care Med 2004, 32:2157-2159.
121. Vodovotz Y., Clermont G., Hunt C.A., et al. Evidence-based modeling of critical illness: an initial consensus from the Society for Complexity in Acute Illness. J Crit Care 2007, 22:77-84.
122. Kumar R., Clermont G., Vodovotz Y., et al. The dynamics of acute inflammation. J Theor Biol 2004, 230:145-155.
123. Gibbs J.B. Mechanism-based target identification and drug discovery in cancer research. Science 2000, 287:1969-1973.
124. Faeder J.R., Hlavacek W.S., Reischl I., et al. Investigation of early events in Fc epsilon RI-mediated signaling using a detailed mathematical model. J Immunol 2003, 170:3769-3781.
125. Rivišre B., Epshteyn Y., Swigon D., et al. A simple mathematical model of signaling resulting from the binding of lipopolysaccharide with Toll-like receptor 4 demonstrates inherent preconditioning behavior. Math Biosci 2009, 217:19-26.
126. Chow C.C., Clermont G., Kumar R., et al. The acute inflammatory response in diverse shock states. Shock 2005, 24:74-84.
127. Reynolds A., Rubin J., Clermont G., et al. A reduced mathematical model of the acute inflammatory response: I. Derivation of model and analysis of anti-inflammation. J Theor Biol 2006, 242:220-236.
128. Day J., Rubin J., Vodovotz Y., et al. A reduced mathematical model of the acute inflammatory response: II. Capturing scenarios of repeated endotoxin administration. J Theor Biol 2006, 242:237-256.
129. Torres A., Bentley T., Bartels J., et al. Mathematical modeling of post-hemorrhage inflammation in mice: studies using a novel, computer-controlled, closed-loop hemorrhage apparatus. Shock 2009, 32:172-178.
130. Foteinou P.T., Calvano S.E., Lowry S.F., et al. Modeling endotoxin-induced systemic inflammation using an indirect response approach. Math Biosci 2009, 217:27-42.
131. Foteinou P.T., Calvano S.E., Lowry S.F., et al. In silico simulation of corticosteroids effect on an NFkB- dependent physicochemical model of systemic inflammation. PLoS ONE 2009, 4:e4706.
132. Kumar R., Chow C.C., Bartels J., et al. A mathematical simulation of the inflammatory response to anthrax infection. Shock 2008, 29:104-111.
133. Arciero J., Rubin J., Upperman J., et al. Using a mathematical model to analyze the role of probiotics and inflammation in necrotizing enterocolitis. PLoS ONE 2010, 5:e10066.
134. Prince J.M., Levy R.M., Bartels J., et al. In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. Mol Med 2006, 12:88-96.
135. Lagoa C.E., Bartels J., Baratt A., et al. The role of initial trauma in the host's response to injury and hemorrhage: Insights from a comparison of mathematical simulations and hepatic transcriptomic analysis. Shock 2006, 26:592-600.
136. Daun S., Rubin J., Vodovotz Y., et al. An ensemble of models of the acute inflammatory response to bacterial lipopolysaccharide in rats: results from parameter space reduction. J Theor Biol 2008, 253:843-853.
137. Foteinou P.T., Calvano S.E., Lowry S.F., et al. Multiscale model for the assessment of autonomic dysfunction in human endotoxemia. Physiol Genomics 2010, 42:5-19.
138. Clermont G., Bartels J., Kumar R., et al. In silico design of clinical trials: a method coming of age. Crit Care Med 2004, 32:2061-2070.
139. An G., Bartels J., Vodovotz Y. In silico augmentation of the drug development pipeline: examples from the study of acute inflammation. Drug Dev Res 2010, 72:1-14.
140. Andreasen A.S., Krabbe K.S., Krogh-Madsen R., et al. Human endotoxemia as a model of systemic inflammation. Curr Med Chem 2008, 15:1697-1705.
141. Foteinou P.T., Calvano S.E., Lowry S.F., et al. A physiological model for autonomic heart rate regulation in human endotoxemia. Shock 2011, (in press).
142. Vodovotz Y. Translational systems biology of inflammation and healing. Wound Repair Regen 2010, 18:3-7.
143. Buchman T.G. In vivo, in vitro, in silico. Crit Care Med 2004, 32:2159-2160.
144. Gullo A., Bianco N., Berlot G. Management of severe sepsis and septic shock: challenges and recommendations. Crit Care Clin 2006, 22:489-501. ix.
145. Lobo S.M., Lobo F.R., Bota D.P., et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003, 123:2043-2049.
146. Ugarte H., Silva E., Mercan D., et al. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999, 27:498-504.
147. Casey L.C., Balk R.A., Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993, 119:771-778.
148. Damas P., Ledoux D., Nys M., et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992, 215:356-362.
149. Friedman G., Jankowski S., Marchant A., et al. Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care 1997, 12:183-187.
150. Pinsky M.R., Vincent J.L., Deviere J., et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993, 103:565-575.
151. Marshall J.C., Foster D., Vincent J.L., et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004, 190:527-534.
152. Gibot S., Kolopp-Sarda M.N., Bene M.C., et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004, 141:9-15.
153. Dempfle C.E., Lorenz S., Smolinski M., et al. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Crit Care Med 2004, 32:520-524.
154. Toh C.H., Ticknor L.O., Downey C., et al. Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation. Intensive Care Med 2003, 29:55-61.
155. Seely A.J.E., Christou N.V. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med 2000, 28:2193-2200. [Review].
156. Schmidt H.B., Werdan K., Muller-Werdan U. Autonomic dysfunction in the ICU patient. Curr Opin Crit Care 2001, 7:314-322.
157. Moorman J.R., Lake D.E., Griffin M.P. Heart rate characteristics monitoring for neonatal sepsis. IEEE Trans Biomed Eng 2006, 53:126-132.
158. Werdan K., Schmidt H., Ebelt H., et al. Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol 2009, 87:266-274.